Pharmacological preconditioning with tumor necrosis factor-α activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase)

Circulation

Volumn 112, Issue 25, 2005, Pages 3911-3918

  Lecour, Sandrine ^a   Suleman, Naushaad ^a   Deuchar, Graeme A ^a   Somers, Sarin ^a   Lacerda, Lydia ^a   Huisamen, Barbara ^b   Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Infarction; Ischemia; Myocardial infarction; Proteins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN; CARDIOTONIC AGENT; STAT3 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DRUG EFFECT; HEART INFARCTION; HEART INFARCTION PREVENTION; IN VITRO STUDY; METABOLISM; METHODOLOGY; PHOSPHORYLATION; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; CELL SURVIVAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644876126     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.581058     Document Type: Article

References (38)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
2. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
3. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol. 2004;44:1111-1112.
4. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK) pathway. Cardiovasc Res. 2004;61:448-460.
5. Downey JM, Cohen MV. We think we see a pattern emerging here. Circulation. 2005;111:120-121.
6. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF-α and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518.
7. Smith RM, Lecour S, Sack MN. Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program. Cardiovasc Res. 2002;55:474-482.
8. Ichikawa Y, Miura T, Nakano A, Miki T, Nakamura Y, Tsuchihashi K, Shimamoto K. The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioning. Cardiovasc Res. 2004;62:167-175.
9. Tanno M, Gorog DA, Bellahcene M, Cao X, Quinlan RA, Marber MS. Tumor necrosis factor-induced protection of the murine heart is independent of p38-MAPK activation. J Mol Cell Cardiol. 2003;35:1523-1527.
10. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNF-α gene. Cardiovasc Res. 2002;55:553-560.
11. Deuchar GA, Smith R, Lecour S, Opie LH. In vivo cardioprotective role of TNF-α. J Mol Cell Cardiol. 2005;38:1016. Abstract.
12. Lecour S, Rochette L, Opie L. Free radicals trigger TNF-α-induced cardioprotection. Cardiovasc Res. 2005;65:239-243.
13. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, Sack MN. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res. 2004;63:611-616.
14. Stephanou A, Brar BK, Scarabelli TM, Jonassen AK, Yellon DM, Marber MS, Knight RA, Latchman DS. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J Biol Chem. 2000;275:10002-10008.
15. Bolli R, Dawn B, Xuan Y. Emerging role of the JAK-STAT pathway as a mechanism of protection against ischemia/reperfusion injury. J Mol Cell Cardiol. 2001;33:1893-1896.
16. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MAQ, Das DK. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol. 2001;33:1929-1936.
17. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci U S A. 2001;98:9050-9055.
18. Jonassen AK, Sack MN, Mjos OD, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-1198.
19. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579-H588.
20. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res. 2004;63:305-312.
21. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004;3:459-463.
22. Minners J, Lacerda L, McCarthy M, Meiring JJ, Yellon DM, Sack MN. Ischemic and pharmacologic preconditioning in Girardi cells and C2C12 myotubes induce mitochondrial uncoupling. Circ Res. 2001;89:787-792.
23. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A. 1997;94:6438-6443.
24. Minners J, van den Bos EJ, Yellon DM, Schwalb H, Opie LH, Sack MN. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res. 2000;47:68-73.
25. Belosjorow S, Bolle I, Duschin A, Heusch G, Schulz R. TNF-α antibodies are as effective as ischemic preconditioning in reducing infarct size in rabbits. Am J Physiol Heart Circ Physiol. 2003;284:H927-H930.
26. Aker S, Belosjorow S, Konietzka I, Duschin A, Martin C, Heusch G, Schulz R. Serum but not myocardial TNF-α concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol. 2003;285:R463-R469.
27. Thielmann M, Dorge H, Martin C, Belosjorow S, Schwanke U, van De Sand A, Konietzka I, Buchert A, Kruger A, Schulz R, Heusch G. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-α, and sphingosine. Circ Res. 2002;90:807-813.
28. Gurevitch J, Frolkis I, Yuhas Y, Paz Y, Matsa M, Moto R, Yakirevich V. Tumor necrosis factor-α is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol. 1996;28:247-252.
29. Vahlhaus C, Schulz R, Post H, Rose J, Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol. 1998;30:197-209.
30. Fryer RM, Schultz JE, Hsu AK, Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. Am J Physiol. 1999;276:H1229-H1235.
31. Ebel D, Mullenheim J, Sudkamp H, Bohlen T, Ferrari J, Huhn R, Preckel B, Schlack W. Role of tyrosine kinase in desflurane-induced preconditioning. Anesthesiology. 2004;100:555-561.
32. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-H976.
33. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res. 2004;95:230-232.
34. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol. 2004;44:1103-1110.
35. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK 1/2. Am J Physiol Heart Circ Physiol. 2005;289:H1618-H1626.
36. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549.
37. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 2003;60:617-625.
38. Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation. 2004;109:1714-1717.